|
|
|
ONLINE FEATURES
Book Reviews
BW Video
Columnists
Interactive Gallery
Newsletters
Past Covers
Philanthropy
Podcasts
Special Reports
BLOGS
Auto Beat
Bangalore Tigers
Blogspotting
Brand New Day
Byte of the Apple
Economics Unbound
Eye on Asia
Fine On Media
Green Biz
Hot Property
Investing Insights
Management IQ
NEXT: Innovation
NussbaumOnDesign
Tech Beat
Working Parents
TECHNOLOGY
J.D. Power Ratings
Product Reviews
Tech Stats
Wildstrom: Tech Maven
AUTOS
Home Page
Auto Reviews
Classic Cars
Car Care & Safety
Hybrids
INNOVATION
& DESIGN Home Page Architecture Brand Equity Auto Design Game Room SMALLBIZ Smart Answers Success Stories Today's Tip INVESTING Investing: Europe Annual Reports BW 50 S&P Picks & Pans Stock Screeners Free S&P Stock Report SCOREBOARDS Hot Growth 100 Mutual Funds Info Tech 100 S&P 500 B-SCHOOLS Undergrad Programs MBA Blogs MBA Profiles MBA Rankings Who's Hiring Grads |  |
SEPTEMBER 18, 2006
Gilead Has "Room To Run"  Most pharmaceutical companies are limping, but Gilead Sciences (GILD
) has sprinted from 53 to 61.54 this year. "Gilead's dominance in anti-HIV drugs continues to drive the stock," says Hans Danielsson of AIG Global Investment Group (AIG
), which owns Gilead shares. At 23 times the consensus 2007 earnings estimate of $2.63 a share, the stock is cheap, says Danielsson, and it has room to run. Better-than-expected second-quarter results showed that Gilead's "exciting products continue to widen its lead in that huge market," he adds. The Food & Drug Administration has approved several of Gilead's anti-HIV drugs, including Atripla, a stand-alone, once-a-day treatment launched in July. Jennifer Chao of Deutsche Bank (DB
) expects Atripla sales to rise from $135 million in 2006 to $2.2 billion in 2008. Chao, who rates Gilead a "buy," expects it to earn $2.43 a share on sales of $2.98 billion this year and $2.87 on $3.8 billion in 2007, up from 2005's $1.66 on $2 billion. Gilead's second-quarter anti-HIV drug sales of $475 million were above analysts' forecasts and 28% up from sales a year ago. Cameron Lavey of Standard & Poor's rates the stock a "buy" and says it deserves a premium rating because of its "predictable growth and dominant position" in the HIV market. He expects Gilead's earnings to increase by an average of 19% a year through 2010. His 12-month target for the stock: 72.
Note: Unless otherwise noted, neither the sources cited in Inside Wall Street nor their firms hold positions in the stocks under discussion. Similarly, they have no investment banking or other financial relationships with them.  By Gene G. Marcial
BW MALL
SPONSORED LINKS
Get BusinessWeek directly on your desktop with our RSS feeds.
Buy a link now! Add BusinessWeek news to your Web site with our headline feed. Click to buy an e-print or reprint of a BusinessWeek or BusinessWeek Online story or video. To subscribe online to BusinessWeek magazine, please click here. Learn more, go to the BusinessWeekOnline home page  | | |
 Copyright 2006, by The McGraw-Hill Companies Inc. All rights reserved.Terms of Use | Privacy Notice |
Printer-Friendly Version